Exelixis, Inc. - Common Stock (NQ:EXEL)

58.66 +0.27 (+0.46%)

Delayed Quote Updated: 12:24 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

23 24 Next >

6 Analysts Have This to Say About Exelixis ↗

December 13, 2023

Via Benzinga

Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023

December 07, 2023

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

December 04, 2023

From Exelixis, Inc.

Via Business Wire

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

December 04, 2023

From Arcus Biosciences

Via Business Wire

NASDAQ:EXEL, a growth stock which is not overvalued. ↗

November 29, 2023

Investors seeking growth at a reasonable cost should explore NASDAQ:EXEL.

Via Chartmill

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

November 29, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023

November 21, 2023

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

November 10, 2023

From Exelixis, Inc.

Via Business Wire

Looking for growth without the hefty price tag? Consider NASDAQ:EXEL. ↗

November 06, 2023

EXELIXIS INC (NASDAQ:EXEL) is showing decent growth, but is still valued reasonably.

Via Chartmill

Where Exelixis Stands With Analysts ↗

November 02, 2023

Via Benzinga

Earnings Outlook For Exelixis ↗

October 31, 2023

Via Benzinga

Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures ↗

November 09, 2023

Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.

Via InvestorPlace

3 Biotech Stocks With the Strongest Clinical Pipelines ↗

November 08, 2023

Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.

Via InvestorPlace

3 Promising Biotech Stocks Flying Under the Radar ↗

November 08, 2023

Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.

Via InvestorPlace

Exelixis (EXEL) Q3 2023 Earnings Call Transcript ↗

November 02, 2023

EXEL earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 01, 2023

From Exelixis, Inc.

Via Business Wire

Is Exelixis Stock a Buy Now? ↗

October 18, 2023

There is one key reason to consider the stock.

Via The Motley Fool

14 Analysts Have This to Say About Exelixis ↗

October 11, 2023

Via Benzinga

4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

October 28, 2023

Bargains abound for growth-seeking investors, with the Nasdaq Composite still 20% below its record-closing high.

Via The Motley Fool

Topics Stocks

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

October 25, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END

Via FinancialNewsMedia

Why Exelixis Stock Is Trading Lower Today ↗

October 23, 2023

Exelixis, Inc. (NASDAQ: EXEL) shares are trading lower on Monday after the company announced detailed results from its Phase 3 CABINET pivotal trial evaluating Cabozantinib in

Via Benzinga

Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

October 22, 2023

From Exelixis, Inc.

Via Business Wire

3 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

October 19, 2023

These three lesser-known biotech companies are profitable and growing revenue.

Via The Motley Fool

Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023

October 18, 2023

From Exelixis, Inc.

Via Business Wire

Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation. ↗

October 13, 2023

EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive.

Via Chartmill

Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains ↗

October 02, 2023

Low-beta stocks provide an avenue for investors looking for long-term growth accompanied by low volatility.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2023 ↗

September 26, 2023

Via Benzinga

3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall ↗

September 20, 2023

Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.

Via InvestorPlace

Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy ↗

September 16, 2023

Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule...

Via Talk Markets

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.